Objective To assess the relationships between fluid and imaging biomarkers of tau pathology and compare their diagnostic utility in a clinically heterogeneous sample. were measured by multianalyte immunoassay (AlzBio3). Receiver operator characteristic analyses were performed to compare discrimination of Aβ-positive AD from non-AD conditions across biomarkers. Correlations between CSF biomarkers and PET standardized uptake value ratios (SUVR) were assessed using skipped Pearson correlation coefficients. Voxelwise analyses were run to assess regional CSF-PET associations. 
Imaging and CSF-based biomarkers both capture key aspects of Alzheimer disease (AD) pathophysiology, including β-amyloid (Aβ) and tau deposition and neurodegeneration. The applications of biomarkers in clinical and research criteria 1, 2 have been predicated on the notion that imaging and CSF biomarkers can be used interchangeably to detect these pathophysiologic processes in individual patients. 3 Indeed, previous studies have demonstrated good agreement between CSF Aβ 42 and Aβ-specific PET ligands in classifying individuals as Aβ-positive or Aβ-negative. 4, 5 CSF measures of phosphorylated tau (p-tau) have been linked to neurofibrillary pathology, whereas CSF total tau (t-tau) is thought to represent a less specific marker of neurodegeneration.
[
18 F]AV1451 is a novel PET radiotracer [6] [7] [8] that binds to the paired helical filaments of tau (PHF-tau) that comprise neurofibrillary tangles. 9, 10 Early studies assessing the relationship between [ 18 F]AV1451-PET and CSF tau measures have reported weak to moderate relationships at the preclinical and predementia stages of AD. 11, 12 Further work in more clinically relevant samples is needed to determine if imaging and fluid biomarkers provide similar information in detecting and quantifying PHF-tau pathology in vivo.
In the present study, we assessed CSF [ 18 F]AV1451-PET relationships in a heterogeneous clinical sample that consisted of patients in more advanced clinical stages of AD (primarily mild dementia) and those with non-AD dementias. We hypothesized that [ 
Methods

Patients
This retrospective study included 53 patients who were recruited from the University of California San Francisco (UCSF) Memory and Aging Center beginning in September 2013 and had available CSF and [ 18 F]AV1451-PET data by February 2017. All patients received a comprehensive clinical evaluation. 8 Clinical diagnosis was established by consensus in a multidisciplinary conference blinded to CSF and PET results. Twenty-five patients were diagnosed with probable AD dementia 1 and 3 patients with mild cognitive impairment (MCI) due to AD. 13 Remaining patients had a clinical diagnosis of a non-AD neurodegenerative disease: progressive supranuclear palsy 14 (n = 7), nonfluent primary progressive aphasia 15 (n = 6), corticobasal syndrome 16 (n = 5), behavioral variant frontotemporal dementia 17 (n = 4) or MCI not due to AD 13 (n = 3).
Patient classification was later refined based on Aβ-PET results (see below and figure 1). Among the 28 patients with a clinical diagnosis of AD, 24 were Aβ-PET-positive (23 using [ Standard protocol approvals, registrations, and patient consents Written informed consent was obtained from all patients or their surrogates. The study was approved by the University of California (San Francisco and Berkeley) and Lawrence Berkeley National Laboratory (LBNL) institutional review boards for human research.
Lumbar puncture
Collection and processing of CSF samples followed Alzheimer's Disease Neuroimaging Initiative protocols (adni.loni.usc.edu/ wp-content/uploads/2008/07/adni2-procedures-manual.pdf). CSF was obtained by lumbar puncture using a 25-G needle and collected in 10-mL polypropylene tubes (Sarstedt; Nümbrecht, Germany). Within 1 hour, CSF was centrifuged at 2,000g for 10 minutes at 4°C, transferred to new polypropylene tubes, and stored at −80°C until biomarker analysis. Analyses were performed at Washington University using INNO-BIA AlzBio3 (Innogenetics; Ghent, Belgium) assay to measure Aβ 42 , p-tau 181, and t-tau, blind to clinical or imaging information.
Imaging Acquisition
Acquisition procedures are fully described in appendix e-1 (links.lww.com/WNL/A70). Briefly, a T1-weighted sequence Glossary Aβ = β-amyloid; AD = Alzheimer disease; AUC = area under the curve; CI = confidence interval; GM = gray matter; LBNL = Lawrence Berkeley National Laboratory; MCI = mild cognitive impairment; MMSE = Mini-Mental State Examination; p-tau = phosphorylated tau; PHF-tau = paired helical filaments of tau; PiB = Pittsburgh compound B; ROC = receiver operating characteristic; SPM12 = Statistical Parametric Mapping 12; SUVR = standard uptake value ratio; t-tau = total tau; UCSF = University of California San Francisco.
was acquired on a 3T Siemens (Munich, Germany) scanner at UCSF while PET scans were performed at LBNL on a Siemens Biograph PET/CT scanner. We analyzed data acquired from 50 to 70 minutes postinjection for 11 
Measures of interest
11 C-PiB scans were visually read as positive or negative by an expert neurologist (G.D.R.) as previously described 20 and global cortical 11 C-PiB SUVR values were extracted in native space using a large Freesurfer-defined cortical region of interest. 21 Two complementary global metrics were extracted from [ 18 F] AV1451 (see appendix e-2 for detailed description, links.lww. com/WNL/A70). First, a mean cortical SUVR was extracted in native space using all Freesurfer-derived cortical regions as an indicator of tau cortical burden. Second, we calculated an index of spatial extent by measuring the percent of GM voxels that had significant elevated [ 18 F]AV1451 binding, as an indicator of the spread of tau pathology. This was done by comparing each patient's warped SUVR image to an independent group of 53 PiB-negative cognitively normal individuals using a W-score procedure adjusting for age. 22, 23 Abnormal voxels were defined as those with W > 2 (corresponding to the 97.7th percentile of a normal distribution), but results were identical when using W > 1.65 (95th percentile) or 3 (99.9th percentile). Note that control individuals did not have CSF data and were solely included to compute W-score maps.
Statistical analyses
Our first objective was to assess the ability of [
18 F]AV1451 and CSF measures to distinguish between patients with AD vs non-AD conditions. Biomarker values were compared between the Aβ-positive AD and non-AD conditions groups using Mann-Whitney tests. Receiver operating characteristic (ROC) analyses were conducted to assess each variable's ability to discriminate the groups; the area under the curve (AUC) and exact binomial 95% confidence intervals (95% CI) were computed. Optimal thresholds were determined using the Youden index. This evidence derived from this study is rated Class III because of the diagnostic case-control design and the risk of spectrum bias (there was little diagnostic uncertainty between the AD cases and non-AD controls). In addition, the patients were included based on the availability of both CSF and [
18 F]AV1451-PET data.
Second, associations between [
18 F]AV1451-PET and CSF measures were assessed using skipped Pearson correlation coefficients 24 ; significance was determined using bootstrap 95% CIs to limit the influence of outliers and data heteroscedasticity. Correlations were assessed twice for each pair of variables: in the full group (n = 53), and in the Aβ-positive AD group (n = 24).
Equivalent analyses were conducted voxelwise using SPM12 2-sample t-test and independent multiple regression routines to perform group comparisons and PET-CSF associations. All results were displayed using a p uncorrected < 0.005 at the voxel level combined with a p FWE-corrected < 0.05 at the cluster level. To simplify the interpretation of voxelwise results, T-maps were transformed to effect size maps (for group comparisons) or correlation coefficient maps (for PET-CSF associations). To mirror the analyses conducted on numerical variables, ROC analyses were run to compare the 2 groups using the Voxelstats toolbox, 25 enabling the computation of AUC values voxelwise.
Third, we conducted analyses on the association between fluid and imaging biomarkers for the other 2 pathologic features of AD: Aβ and neurodegeneration. 3 We assessed correlations between (1) CSF Aβ 42 levels and cortical PiB SUVR values and (2) CSF t-tau levels and GM volumes in a voxelwise SPM12 analysis controlling for intracranial volume. 
Results
Group comparison
Patient demographics are shown in the table. Groups were matched for sex, education, and PET-CSF time difference, but the Aβ-positive AD group tended to be slightly younger and more impaired than the non-AD conditions group. 18 F]AV1451 cortical SUVR and spatial extent, the former showing a uniform distribution while the latter follows a more bimodal pattern that splits between the AD and non-AD groups, the patterns of correlations with CSF biomarkers were comparable.
In the full sample, all CSF biomarkers significantly correlated with [ 18 F]AV1451 indices (all |r|s > 0.49, with negative values for CSF Aβ 42 and positive values for p-tau and t-tau), with maximal correlations (r = 0.75) found for CSF p-tau. As all 3 CSF biomarkers were correlated (see figure e-1, links.lww. com/WNL/A69), they were included in a robust (bisquare) When restricted to the Aβ-positive AD group, CSF Aβ 42 was no longer associated with [
18 F]AV1451 (figure 4). CSF p-tau and t-tau showed voxelwise associations that were comparable, but less extensive than in the full sample analyses, with a dorsal-posterior pattern for the former contrasting with a ventral-anterior pattern for the latter. The reduction in statistical significance was not only due to a decrease in statistical power (going from n = 53 to n = 24), but also to a drop in r values (see histograms in figure 4).
Fluid vs imaging classification as tau-positive: Performance and outliers
Using the thresholds derived from our ROC analyses (see above) to classify patients as tau-positive or tau-negative, CSF p-tau and [ 18 Regarding neurodegeneration biomarkers, voxelwise analyses showed that higher CSF t-tau was mildly associated with lower right parietal volumes (reaching r = −0.50) when all patients were included, while no relationship remained significant when restricting the analysis to the Aβ-positive AD group (figure e-3, links.lww.com/WNL/A69).
Discussion
In this study, we sought to examine relationships between [ , and 3rd quartiles (black lines). Groups were compared using Mann-Whitney test (corresponding Z value is indicated; ***p < 0.001), and a ROC analysis was run to obtain AUC value (with binomial exact 95% confidence interval) and optimal threshold according to the Youden index. p-tau = Phosphorylated tau; t-tau = total tau. that considers tau-PET and CSF p-tau as the relevant biomarkers to classify individuals as tau-positive or tau-negative. In our cohort, the agreement between fluid and PET biomarkers of tau was in the range of what has been reported for Aβ markers. 4, [27] [28] [29] [30] In contrast, the existing literature indicates that fluid and imaging biomarkers of neurodegeneration are poorly associated (κ values are systematically below 0.4 30, 31 ), in line with the mild correlations we observed between CSF t-tau and GM volumes in the full group.
It is important to note that our non-AD group included patients with syndromes that are associated with a high likelihood of underlying non-AD tauopathies. For instance, 88% of patients with nonfluent primary progressive aphasia seen at our center were shown to have tau pathology at autopsy. 32 Yet both [ 18 F]AV1451 and CSF p-tau discriminated the non-AD group from Aβ-positive patients with AD, highlighting that both these biomarkers are more strongly linked to PHF-tau than to other forms of tauopathy. Our results are consistent with previous reports on the specificity of CSF p-tau, 33 and with postmortem and in vivo studies indicating a higher affinity of [
18 F]AV1451 for PHF-tau compared to other tauopathies. 9, 10 In contrast with the high CSF/PET associations observed in the full group, correlations were mild when restricted to the Aβ-positive AD group, dropping to below r = 0.5 for global indices of [ 18 F]AV1451-PET (i.e., less than 25% of shared variance), similar to previously reported correlations in cognitively normal older adults. 11 This pattern was even more pronounced for biomarkers of Aβ and neurodegeneration, as Interestingly, and although this is still debated, 34 accumulating evidence suggests that CSF p-tau may increase in an early disease stage and later decrease in symptomatic patients with AD. [35] [36] [37] It has therefore been hypothesized that early p-tau increases reflect the progression of tau pathology throughout the brain (i.e., when the size of neuronal populations developing tau pathology increases) 36 while p-tau would later decrease due to the death of neurons. Alternatively, p-tau might become sequestrated in tangles. CSF p-tau levels would therefore be expected to vary nonlinearly by disease stage whereas [
18 F]AV1451-PET signal might reflect the overall accumulation of pathology. This is supported by the current data showing that lower MMSE was correlated with increased [
18 F]AV1451-PET binding, but not CSF p-tau in the AD group. Assessing longitudinal changes in both p-tau and [ 18 F] AV1451-PET is necessary to determine the specific dynamics of each marker.
It should be noted that patterns of correlations and diagnostic properties were highly similar using [ 18 F]AV1451 cortical SUVR and spatial extent, in spite of the different statistical distributions of these global measures. Voxelwise analyses suggest that a more regional approach targeting specific regions (e.g., precuneus) might help strengthen the correlations between p-tau and tau-PET within the AD group.
Comparison of the correlation patterns observed between [
18 F]AV1451 PET and CSF p-tau vs CSF t-tau revealed an interesting pattern, in spite of the strong intercorrelation of these 2 biomarkers. At the full group level, [ 18 F]AV1451 was more strongly correlated with CSF p-tau than CSF t-tau, consistent with the idea that p-tau is a better marker of PHF tau pathology than t-tau. 3 However, this hierarchy disappeared when restricting the analyses to the Aβ-positive AD group. Moreover, the voxelwise regression analyses showed a differential pattern of regional correlation, with CSF p-tau correlating with temporoparietal [
18 F]AV1451 (the areas of highest and most frequent uptake in AD) while CSF t-tau was associated with [ 18 F]AV1451 in prefrontal cortex, an area affected by tau in later stages of AD. 38 Given the modest size of our Aβ-positive AD group, we consider this finding preliminary. However, if replicated in larger samples, this finding could indicate that elevated t-tau is a marker of more advanced disease stage as defined by more widespread tau pathology and neurodegeneration.
Our study has limitations. The sample size was modest (though comparable to previous tau-PET vs CSF studies). Our patients on average represented an early age at onset dementia cohort, in which contrasts in CSF and PET measures of tau may be heightened in AD vs non-AD conditions compared to older cohorts. CSF data were only available in symptomatic patients while data from cognitively normal controls would provide data on earlier stages of tau pathology, allowing better characterization of CSF imaging relationships across the AD continuum. Finally, the cross-sectional nature of our study does not allow us to clearly determine the actual ordering and evolution of biomarker abnormalities over time.
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